All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Could ponatinib + blinatumomab substitute chemo + allo-HSCT as frontline therapy for Ph+ ALL?
Bookmark this article
During the 2021 ASCO Annual Meeting and the EHA 2021 Virtual Congress, the ALL Hub spoke with Nicholas Short, MD Anderson Cancer Center, Houston, US. We asked, Could ponatinib + blinatumomab substitute chemo + allo-HSCT as frontline therapy for Philadelphia-positive (Ph+) ALL?
Could ponatinib + blinatumomab substitute chemo + allo-HSCT as frontline therapy for Ph+ ALL?
Short presents promising safety and efficacy data from a single-arm phase II study investigating a combination of ponatinib + blinatumomab, in adult patients with newly diagnosed or relapsed/refractory Ph+ ALL.
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox